Zhao Xiaohu, Liu Jingxuan, Li Dake, Si Shangkun, Tian Xuanhe, Zhang Deke, Jiang Ping
The First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Department of Rheumatology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Yantai, China.
Front Med (Lausanne). 2025 Aug 4;12:1602699. doi: 10.3389/fmed.2025.1602699. eCollection 2025.
BACKGROUND: Acupuncture has been listed as an alternative treatment in several knee osteoarthritis (KOA) international guidelines. Fu's subcutaneous needling (FSN), as a novel acupuncture therapy, has shown greater potential for treating KOA. The objective of this systematic review is to compare the efficacy and safety of FSN to routine acupuncture therapy (RAT) for KOA. METHODS: China National Knowledge Infrastructure, VIP, China Biomedical Literature Database, Wanfang Medical, Embase, PubMed, Ovid, and the Cochrane Library were searched from inception to March 2025, and randomized controlled trials on FSN for KOA were included. The primary outcomes were total efficacy rate, Visual Analog Scale (VAS) pain scores and Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores. Literature quality was assessed using Cochrane risk-of-bias tool 1.0. Heterogeneity among trials was assessed using the Cochrane test and values, determining model selection (fixed/random effects). The meta-analyses of included studies used odds ratios and mean differences when appropriate, along with significance threshold = 0.1. The evidence was evaluated by the GRADE guideline. The PROSPERO International Prospective Register of Systematic Reviews received this research for registration (CRD42024595903). RESULTS: A total of 14 studies were included (1,186 patients, with 594 in FSN group and 592 in RAT group). Primary outcomes: The total efficacy rate of the FSN group was significantly higher than that of the RAT group [OR = 3.83, 95% CI (2.36, 6.91), < 0.01, = 10, 470/467 participants]. FSN also demonstrated greater effectiveness in reducing VAS pain scores [MD = -1.44, 95% CI (-1.62, -1.26), < 0.01, = 6, 205/206 participants] and WOMAC scores [MD = -6.07, 95% CI (-8.16, -3.97), < 0.01, = 5, 160/161 participants]. Secondary outcomes: FSN group showed a greater reduction in inflammatory cytokines: IL-6 [MD = -1.50 ng/mL, 95% CI (-1.55, -1.46), < 0.01, = 4, 180/180 participants], TNF-α [MD = -2.26 pg/mL, 95% CI (-2.30, -2.23), < 0.01, = 4, 180/180 participants]. CONCLUSION: Compared to RAT for KOA, FSN demonstrates superior efficacy in alleviating pain, reducing inflammation, and improving joint dysfunction. Further high-quality studies are needed to determine the long-term efficacy of FSN. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024595903.
背景:针灸已被列入多项膝关节骨关节炎(KOA)国际指南的替代治疗方法。浮针疗法(FSN)作为一种新型针灸疗法,在治疗KOA方面显示出更大的潜力。本系统评价的目的是比较FSN与常规针灸疗法(RAT)治疗KOA的疗效和安全性。 方法:检索中国知网、维普、中国生物医学文献数据库、万方医学、Embase、PubMed、Ovid和Cochrane图书馆,检索时间从建库至2025年3月,纳入关于FSN治疗KOA的随机对照试验。主要结局指标为总有效率、视觉模拟评分法(VAS)疼痛评分和西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分。采用Cochrane偏倚风险工具1.0评估文献质量。采用Cochrane Q检验和I²值评估各试验间的异质性,确定模型选择(固定/随机效应)。纳入研究的荟萃分析在适当情况下使用比值比和均值差,显著性阈值α=0.1。证据按照GRADE指南进行评估。本研究已在PROSPERO国际系统评价前瞻性注册库注册(CRD42024595903)。 结果:共纳入14项研究(1186例患者,FSN组594例,RAT组592例)。主要结局:FSN组的总有效率显著高于RAT组[比值比(OR)=3.83,95%置信区间(CI)(2.36,6.91),P<0.01,I²=10,470/467例参与者]。FSN在降低VAS疼痛评分[均值差(MD)=-1.44,95%CI(-1.62,-1.26),P<0.01,I²=6,205/206例参与者]和WOMAC评分[MD=-6.07,95%CI(-8.16,-3.97),P<0.01,I²=5,160/161例参与者]方面也显示出更大的效果。次要结局:FSN组炎症细胞因子的降低幅度更大:白细胞介素-6[MD=-1.50 ng/mL,95%CI(-1.55,-1.46),P<0.01,I²=4,180/180例参与者],肿瘤坏死因子-α[MD=-2.26 pg/mL,95%CI(-2.30,-2.23),P<0.01,I²=4,180/180例参与者]。 结论:与RAT治疗KOA相比,FSN在缓解疼痛、减轻炎症和改善关节功能障碍方面显示出更好的疗效。需要进一步开展高质量研究以确定FSN的长期疗效。 系统评价注册:https://www.crd.york.ac.uk/PROSPERO/view/CRD42024595903。
Front Med (Lausanne). 2025-8-4
Cochrane Database Syst Rev. 2015-1-28
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2013-12-9
Cochrane Database Syst Rev. 2015-10-22
Cochrane Database Syst Rev. 2017-12-22
Medicine (Baltimore). 2023-10-27